Effects of Telmisartan on Ischemic Cardiovascular Events in High-risk Hypertensive Patients

Effects of Telmisartan Compared With Candesartan on Ischemic Cardiovascular Events in High-risk Hypertensive Patients: a Multi-center, Prospective, Randomized, Open-labeled, Blinded Endpoints Trial

Status

Terminated

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00863980

Acronym

KCPS

Enrollment

1500

Registered

2009-03-18

Start date

2009-04-30

Completion date

2013-07-31

Last updated

2015-09-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Coronary Syndrome, Acute Myocardial Infarction, Angina Pectoris, Hypertension, Myocardial Ischemia

Keywords

angiotensin, receptor, vulnerable plaque, coronary artery

Brief summary

This study is aimed to investigate whether treatment with Telmisartan is more effective than Candesartan in reducing the ischemic cardiovascular events in high-risk patients with cardiovascular disease.

Detailed description

Interventions

DRUGMicardis (Telmisartan)

40-80 mg/day oral administration

DRUGBlopress (Candesartan)

8-12 mg/day oral administration

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Masking

SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

30 Years to 85 Years

Healthy volunteers

Inclusion criteria

The inclusion criteria are set by at least one of the three following risk factors: 1. Coronary artery disease documented by at least one of the following: * Myocardial infarction at least 12 months before enrollment and not planned for percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG) * Angina pectoris or asymptomatic myocardial ischemia undergoing percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG) at least 12 months before enrollment and not planned for further percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG) 2. Peripheral arterial disease undergoing percutaneous transluminal angioplasty (PTA) or peripheral artery bypass grafting at least 6 months before enrollment 3. Symptomatic cerebral infarction or cerebral hemorrhage at least 6 months before enrollment

Exclusion criteria

The

Design outcomes

Primary

Measure	Time frame
New or recurrent acute myocardial infarction and angina pectoris	3 years

Secondary

Measure	Time frame
All causes of mortality, cardiovascular death, new or recurrent stroke or peripheral artery diseases, new occurrence of diabetes mellitus	3 years

Countries

Japan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026